Navigation Links
Echo Therapeutics Reports Third Quarter 2007 Results
Date:11/20/2007

t to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to risks and uncertainties relating to our ability to develop, market and sell pharmaceutical or diagnostic products based on our AzoneTS and CTGM technologies, including AzoneTS-based Durhalieve for corticosteroid responsive dermatoses and the use of our SonoPrep ultrasound-mediated skin permeation technology platform with our CTGM system for the diabetes home use and hospital intensive and critical care markets; the success of our AzoneTS and CTGM business, research, development, and regulatory approval, marketing and distribution plans and strategies; and, our ability to raise sufficient capital in the future to fund our research and development programs, commercialize our product candidates and achieve profitability. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-KSB for the year ended December 31, 2006, our most recent quarterly reports on Form 10-QSB, and our current reports on Form 8-K. Echo Therapeutics, Inc. does not undertake to update these forward- looking statements.

Investor Relations Contacts:

Patrick T. Mooney, M.D., CEO

508-530-0329

pmooney@echotx.com

10 Forge Parkway

Franklin, MA 02038, USA

Tel: 1+ 877-476-6878

Fax: 1+ 508-553-8760

http://www.echotx.com

All rights reserved worldwide.

Echo Therapeutics, Inc.

(Formerly Sontra Medical Corporation)

Consolidated Balance Sheets

As of,

September 30, December 31,


'/>"/>

SOURCE Echo Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... WABC Radio show out of New York City, ... will be hosting California-based Vet-Stem, Inc.’s Founder and CEO, Robert ... pets. Dr. Harman first visited the show in November ... pets suffering from osteoarthritis and other degenerative diseases, as well ... , Young has invited Dr. Harman back to dial down ...
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/25/2014)... -- Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... , today announced that it will release its unaudited financial ... market close on Thursday, August 14, 2014 EDT. The Company ... on Friday, August 15, 2014, at 8:00 a.m. EDT (Friday, ... review the Company,s financial results and provide an update on ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3
... China Yingxia,International, Inc. (OTC Bulletin Board: CYXI) ("China ... health and nutritional food industry,engaged in the development, ... and raw cactus plants in the People,s,Republic of ... Mr. Ren,Hu will present at the upcoming Roth ...
... Uroplasty, Inc. (Amex:,UPI) announced today that it will ... on Monday, November 10, 2008 at the New York,Palace ... Chief Executive,Officer and Medi Jiwani, Vice President and Chief ... financial,performance at 4:55 p.m. Eastern Time., Attendance at ...
... in medicine. Although no significant achievements for curing disease have been achieved, ... approaches. By the year 2015, global market for gene therapy is projected ... ... 2008 -- Advancements in gene therapy have provided useful data, which has ...
Cached Biology Technology:China Yingxia to Present at Roth China Comes to Vegas Conference 2Uroplasty to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York 2World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc. 2World Gene Therapy Market to Reach $484 Million by 2015, According to New Report by Global Industry Analysts, Inc. 3
(Date:7/25/2014)... Nearly 600 scientists from 25 countries and ... Meeting organized by the Genetics Society of America ... in Seattle. The conference will feature close to ... results on topics including gene expression and regulation, ... technologies, evolution, aging, and a variety of diseases. ...
(Date:7/25/2014)... healthcare community and remain priority areas that ... the worldwide crisis of obesity and diabetes, ... in diabetes, epidemiology and public health describe ... of diverse intervention programs in this novel ... on "Global Health Perspectives in Prediabetes and ...
(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... the AIDS virus,s protein envelope once considered an improbable target ... most promising, new research by Dana-Farber Cancer Institute scientists indicates. ... the V3 loop, is an attractive vaccine target because immune ... multiple genetic subtypes of HIV-1, the virus that causes AIDS. ...
... "skin" of most every cell in your body, but the ... be rendered by many experimental techniques. A team of scientists ... and University of California, Irvine, recently developed a way to ... role of cholesterol within this boundary between the cell and ...
... Minnesota finalized a license agreement for CaSTT (Commerce and ... for technology transfer offices in universities and research institutions. ... consulting services that allow technology transfer offices to make ... and, in some cases, execute licenses from start to ...
Cached Biology News:Study identifies promising target for AIDS vaccine 2Study identifies promising target for AIDS vaccine 3Closer look at cell membrane shows cholesterol 'keeping order' 2